Other Clinical Trial - A Phase I/II Trial of VB-111 & Paclitaxel for

See also
Status	Clinical Trial	Phase
Terminated	`NCT02641639` - FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer	Phase 2/Phase 3
Active, not recruiting	`NCT03552471` - Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer	Phase 1
Active, not recruiting	`NCT03319628` - First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b	Phase 1/Phase 2

See also

Status

Clinical Trial

Phase

Terminated

NCT02641639 - FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer

Phase 2/Phase 3

Active, not recruiting

NCT03552471 - Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Phase 1

Active, not recruiting

NCT03319628 - First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b

Phase 1/Phase 2

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT01711970
Study type	Interventional
Source	Vascular Biogenics Ltd. operating as VBL Therapeutics
Contact
Status	Completed
Phase	Phase 1/Phase 2
Start date	November 2012
Completion date	May 3, 2017

A Phase I/II Trial of VB-111 and Paclitaxel for Recurrent Platinum-Resistant Müllerian Cancer

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms